Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002970 · ClinicalTrials.gov registry record · Phase 2
506U78 in Treating Patients With Refractory Hematologic Cancer
A Phase 2 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Lymphoblastic Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 1
- Study location
NCT00002970: Completed Phase 2 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Lymphoblastic Lymphoma, sponsored by National Cancer Institute (NCI).
NCT00002970 is a Phase 2 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Lymphoblastic Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 148 participants, above the 114-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002970, a Phase 2 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Lymphoblastic Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Primary Outcome
CR is defined by an M1 marrow which requires blast counts below 5%. PR is defined by an M2 marrow which requires blast counts below 25%.
Conditions Studied
Interventions
- DRUG methotrexate
- DRUG cytarabine
- DRUG therapeutic hydrocortisone
- DRUG nelarabine
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 1997-06 |
| Phase | Phase 2 |
What the finished NCT00002970 record still lists
NCT00002970 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 114-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (30% higher).
The record links to 3 conditions, with Recurrent Childhood Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which methotrexate is the first listed.
NCT00002970 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00002970 about?
NCT00002970 is a clinical study titled "506U78 in Treating Patients With Refractory Hematologic Cancer". Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00002970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 1997-06.
What conditions does trial NCT00002970 study?
This clinical trial studies the following conditions: Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT00002970?
The interventions under investigation include: methotrexate (DRUG), cytarabine (DRUG), therapeutic hydrocortisone (DRUG), nelarabine (DRUG).
Who is sponsoring clinical trial NCT00002970?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002970 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002970's enrollment target sits among peer trials
148 3rd of 11 higher than 9 of 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Childhood Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
ACTIVE NOT RECRUITING · Phase 2
-
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
RECRUITING · Phase 1
-
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia
COMPLETED
-
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia